Nektar Therapeutics (NKTR)

[surf1944]

8:33AM Nektar Therapeutics intiates investigator-initiated trial evaluating Etirinotecan Pegol as a third-line treatment in patients with metastatic and recurrent non-small cell lung cancer (NKTR) 8.88 : Co announces the start of a Phase 2 investigator-initiated study of etirinotecan pegol in patients with metastatic and recurrent NSCLC. The primary endpoint of the Phase 2 study is overall response rate. Secondary endpoints include progression free survival, overall survival, median duration of response and the safety profile of etirinotecan pegol in patients with NSCLC after failure of second-line therapy. The open label, single-arm trial is expected to enroll ~37 patients who will receive etirinotecan pegol once every 3 weeks as monotherapy.